Frankfurt - Delayed Quote EUR

Veracyte, Inc. (12V.F)

25.20
0.00
(0.00%)
At close: May 16 at 8:01:02 AM GMT+2
Loading Chart for 12V.F
  • Previous Close 25.20
  • Open 25.20
  • Bid 26.20 x 36100
  • Ask 26.40 x 34700
  • Day's Range 25.20 - 25.20
  • 52 Week Range 18.90 - 44.60
  • Volume 261
  • Avg. Volume 5
  • Market Cap (intraday) 2.043B
  • Beta (5Y Monthly) 2.15
  • PE Ratio (TTM) 66.32
  • EPS (TTM) 0.38
  • Earnings Date Aug 4, 2025 - Aug 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

www.veracyte.com

824

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 12V.F

View More

Performance Overview: 12V.F

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

12V.F
34.38%
S&P 500 (^GSPC)
1.30%

1-Year Return

12V.F
17.76%
S&P 500 (^GSPC)
12.48%

3-Year Return

12V.F
47.25%
S&P 500 (^GSPC)
48.66%

5-Year Return

12V.F
13.51%
S&P 500 (^GSPC)
108.07%

Compare To: 12V.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 12V.F

View More

Valuation Measures

As of 5/16/2025
  • Market Cap

    2.04B

  • Enterprise Value

    1.83B

  • Trailing P/E

    67.16

  • Forward P/E

    21.14

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.84

  • Price/Book (mrq)

    1.85

  • Enterprise Value/Revenue

    4.42

  • Enterprise Value/EBITDA

    38.11

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.13%

  • Return on Assets (ttm)

    1.94%

  • Return on Equity (ttm)

    2.86%

  • Revenue (ttm)

    463.39M

  • Net Income Avi to Common (ttm)

    33.05M

  • Diluted EPS (ttm)

    0.38

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    287.36M

  • Total Debt/Equity (mrq)

    4.23%

  • Levered Free Cash Flow (ttm)

    76.93M

Research Analysis: 12V.F

View More

People Also Watch